These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9426744)

  • 21. Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect.
    Bennett CL; Raisch DW; Sartor O
    Ann Intern Med; 2002 Oct; 137(7):625. PubMed ID: 12353966
    [No Abstract]   [Full Text] [Related]  

  • 22. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
    Takeshita H; Kawakami S; Fukui I
    Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of bicalutamide-induced breast events.
    Sieber PR
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
    Fradet Y; Egerdie B; Andersen M; Tammela TL; Nachabe M; Armstrong J; Morris T; Navani S
    Eur Urol; 2007 Jul; 52(1):106-14. PubMed ID: 17270340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade.
    Castro Beza I; Sánchez Ruiz J; Peracaula Espino FJ; Villanego Beltrán MI
    Clin Transl Oncol; 2008 Sep; 10(9):591-2. PubMed ID: 18796378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
    J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fulminant liver failure induced by flutamide].
    Rodríguez Gómez SJ; Martínez Moreno J; Martín Arribas MI; Pérez Villoria A; De la Serna Higuera C; Betancourt González A
    Rev Esp Enferm Dig; 2000 Jun; 92(6):411. PubMed ID: 10985104
    [No Abstract]   [Full Text] [Related]  

  • 35. [Fulminant liver failure with a fatal outcome due to flutamide].
    Fernández Peña CM; Morano Amado LE; Montes Santiago J; Fachal C
    Med Clin (Barc); 1997 Feb; 108(6):237-8. PubMed ID: 9102495
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined androgen blockade: an update.
    Klotz L
    Urol Clin North Am; 2006 May; 33(2):161-6, v-vi. PubMed ID: 16631454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Severe toxic hepatitis during flutamide (Eulexin) treatment].
    Møller S; Iversen P
    Ugeskr Laeger; 1989 Jan; 151(3):173-4. PubMed ID: 2911917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.